Top Phoenix, AZ Biotech Companies (25)
Don't see your company?
Create a company profile
Trusted by the world's leading organizations, Point B is a consulting firm that works at the intersection of expertise, industry insight, and transformative technology. This collaborative approach enables you to solve your most important challenges, by bringing together the right mix of talent and technology to deliver greater value and impact. With over 850 associates in the US and 3000+ consultants around the world through our Nextcontinent partnership, we work where you do to deliver the change you seek.
Stryker is a global leader in medical technologies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in MedSurg, Neurotechnology, Orthopaedics and Spine that help improve patient and healthcare outcomes. Alongside its customers around the world, Stryker impacts more than 130 million patients annually. More information is available at www.stryker.com. Together with our customers, we are driven to make healthcare better.
Caris Life Sciences was founded in 2008 with a simple but powerful purpose – to help improve the lives of as many people as possible. With transformative technologies informed by massive amounts of big data, we are revolutionizing healthcare to provide physicians and patients with the highest quality information about their disease – from detecting it early and determining how best to treat it, to developing the next wave of novel therapies.
VisionGate, Inc., is a breakthrough liquid-biopsy technology company, leading the battle against lung cancer through early detection technology with a simple, non-intrusive sputum test. The foundation for our diagnostics capability is the proprietary Cell-CT™ 3-Dimensional Cell Imaging and Analysis platform. The Cell-CT platform, using a process called optical computed tomography (CT), produces 3D images of individual cells with the ability to morphologically recognize over 700 structural biomarkers of normal and abnormal cells. The Cell-CT platform can process any liquid biopsy specimen and therefore has potential applicability to detect a wide range of different cancers and cancer biosignatures that could aid in identifying potential treatments using targeted pharmaceutical therapies. Our lead diagnostic product is the LuCED® lung test - a non-invasive sputum-based test that detects abnormal cells which indicate lung cancer and bronchial dysplasia. LuCED lung test utilizes the Cell-CT platform and is in development for the early detection of lung cancer, bronchial dysplasia and the assessment of indeterminate pulmonary nodules (IPN). The LuCED test includes CellGazer™ application, an imaging software tool under development to facilitate cytopathology diagnosis of abnormal cell images detected by the Cell-CT platform. Visit www.visiongate3d.com to learn more.
Humabiologics is a regenerative medicine startup to address the gap between the gift of donated human tissues and researchers.
.jpg)
Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.
Discover the benefits of Nucleic Acid Programmable Protein Arrays(NAPPA). The Ordinatrix team includes co-founders Prof. Josh LaBaer and Prof. Ji Qiu from Arizona State University, joined with biotech/life science executive Jim Hauert. Our goal is to be the leader in translational proteomics through the creation of the most functional, flexible, and precise protein microarrays in the industry based on our attention to quality, intellectual property, and many years of experience with the Nucleic Acid Programmable Protein Arrays (NAPPA) technology, which will aid in the development of new drugs, diagnosis of disease and approaches to personalized medicine.
Systems Oncology is developing a new class of multimodal RNA therapeutics that can simultaneously silence numerous disease targets with a single RNA molecule to improve outcomes and combat emerging drug resistance. Our Arromer platform is used to digitally engineer and rapidly produce self-delivering therapeutics which target specific tissues with unprecedented precision and accuracy. We are focused on building a pipeline of products in oncology, yet our multimodal RNA platform can be harnessed to transform outcomes for any complex polygenic disease.
Discovery Scientific Solutions supplies innovative laboratory equipment, technology, and consultation for the scientific research community.
Amnio Technology is a company based out of 22510 N 18TH DR, PHOENIX, Arizona, United States.
Beacon Biomedical is a biotech company, focuses on developing and commercializing waived tests for earlier cancer detection.
We focus on genomic technologies and provide complete solutions for gene profiling and screening for all life science applications. By means of integrating high-throughput laboratory and microarray fabrication facilities, GenoSensor has become a nationwide leading company in bioassay services and development. Our COVID-19 test kit assays 3 target genes unique to SARS-CoV-2 having higher specificity and exhibiting lower risk for mutation. Our kit is simple to use and ready to utilize in all-in-one master mix reagents and controls minimize variability.
TGen, an affiliate of City of Hope, is a non-profit 501(c)(3) organization focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics and treatments for cancer, neurological disorders, rare childhood disorders, infectious disease and other complex conditions. Stay up-to-date: tgen.org/subscribe
A regenerative medicine company focused on the body performing optimally
Exploragen builds innovative tools and products that connect individuals’ unique DNA to engaging, fun experiences and information. Apps like SlumberType are the first step in this exploration of Bringing DNA to Life.
Creative Medical Technology Holdings is a biotechnology company committed to improving patient lives in the areas of Urology, Neurology.
To use Susavion’s patented MultiValent Peptide Mimetic (MVPM) Technology platform to harness the innate power of the immune system to combat diseases with non-toxic, safe and effective treatments. At Susavion, we pride ourselves on doing things differently. We’re at the forefront of scientific innovation, leading the charge in the effort to solve some of healthcare’s most intractable problems. Our revolutionary therapy is safe and nontoxic, and we care about the people our research will benefit—always balancing our cutting-edge technology with our humanity.
MTI was established as a research and development company with a mission of developing a wide variety of products.
OncoMyx Therapeutics targets hematologic and solid tumors with unique oncolytic virus called myxoma (MYXV) and a novel patented systemic delivery approach. The myxoma program is the result of two decades of oncolytic virus research in the laboratory of Professor Grant McFadden. Myxoma is a pox virus that is highly immunostimulatory, and is non-pathogenic in any organism outside of rabbits. The virus has a unique ability to be carried systemically by human leukocytes where it can then infect tumor cells. Programs are in development for both hematology (myeloma and AML) as well as solid tumors. Professor McFadden sequenced the myxoma virus genome in 1999, and since then has produced dozens of genetically engineered constructs, demonstrating its ability as an oncolytic agent across many tumors in preclinical cell and animal models.
Twenty years ago, we pioneered the world's first clear aligners. Since then, we have continuously innovated with new products and technologies that are revolutionizing treatments for doctors and their patients. Invisalign clear aligners and the iTero Intraoral scanner help dental professionals achieve the clinical results they expect and deliver effective, advanced dental options to their patients. Helping change millions of lives, one smile at a time. Discover your straight path to a bright future at Align. As a part of our smart, diverse and fast-moving global team, you'll make an impact for the market leader that's moving an industry forward. Want to find out what’s next for us—and for you?
Work Your Passion. Live Your Purpose.
